Auna (NYSE:AUNA) President Leon Jesus Zamora Acquires 23,273 Shares

Posted by Stanley Muller on May 29th, 2026

Auna S.A. (NYSE:AUNA – Get Free Report) President Leon Jesus Zamora purchased 23,273 shares of the company’s stock in a transaction dated Wednesday, May 27th. The shares were acquired at an average price of $4.20 per share, for a total transaction of $97,746.60. Following the purchase, the president directly owned 62,710 shares in the company, valued at approximately $263,382. The trade was a 59.01% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Leon Jesus Zamora also recently made the following trade(s):

On Tuesday, May 26th, Leon Jesus Zamora purchased 8,727 shares of Auna stock. The shares were acquired at an average price of $4.24 per share, for a total transaction of $37,002.48.

Auna Trading Up 0.8%

Shares of Auna stock opened at $4.20 on Friday. The company’s fifty day simple moving average is $5.25 and its 200-day simple moving average is $5.02. The stock has a market capitalization of $310.47 million, a PE ratio of 16.14 and a beta of 1.03. Auna S.A. has a 1-year low of $4.13 and a 1-year high of $6.85. The company has a debt-to-equity ratio of 1.76, a current ratio of 1.09 and a quick ratio of 1.00.

Auna (NYSE:AUNA – Get Free Report) last issued its quarterly earnings results on Friday, May 15th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.14). Auna had a return on equity of 16.25% and a net margin of 1.53%.The business had revenue of $336.84 million for the quarter, compared to analysts’ expectations of $320.54 million. As a group, equities analysts anticipate that Auna S.A. will post 0.85 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on AUNA. JPMorgan Chase & Co. lowered their target price on shares of Auna from $6.00 to $5.00 and set a “neutral” rating on the stock in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Auna in a research note on Friday, March 27th. Wall Street Zen lowered Auna from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 16th. Finally, Zacks Research lowered Auna from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $6.97.

Check Out Our Latest Research Report on AUNA

Hedge Funds Weigh In On Auna

Hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its stake in Auna by 487.7% in the 1st quarter. Renaissance Technologies LLC now owns 668,457 shares of the company’s stock worth $3,683,000 after purchasing an additional 554,707 shares in the last quarter. Marshall Wace LLP lifted its stake in Auna by 391.0% in the 4th quarter. Marshall Wace LLP now owns 162,992 shares of the company’s stock worth $802,000 after purchasing an additional 129,799 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in Auna in the 1st quarter worth $557,000. Hsbc Holdings PLC purchased a new stake in Auna in the 1st quarter worth $324,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in Auna in the 1st quarter worth $316,000.

Auna Company Profile

(Get Free Report)

Auna, listed on the New York Stock Exchange under the ticker symbol AUNA, is a Peruvian integrated healthcare services company headquartered in Lima. The firm operates a diversified care network that spans hospitals, outpatient medical centers, diagnostic imaging and laboratory facilities, as well as optical and dental clinics. Auna’s organizational structure is designed to support a continuum of care model, offering both general and specialized treatments across multiple touchpoints.

The company delivers a broad range of clinical services, including emergency care, inpatient and outpatient surgery, obstetrics, cardiology, oncology, orthopedics, and other specialized disciplines.